-
Will thrombopoietin receptor agonists become a treatment option for pediatric chronic immune thrombocytopenia in the future?
Gregory Cheng
Clinical Trail Perspective: Clinical Investigation
-
Will thrombopoietin receptor agonists become a treatment option for pediatric chronic immune thrombocytopenia in the future?
Gregory Cheng
Clinical Trail Perspective: Clinical Investigation
-
Will thrombopoietin receptor agonists become a treatment option for pediatric chronic immune thrombocytopenia in the future?
Gregory Cheng
Clinical Trail Perspective: Clinical Investigation
-
Will thrombopoietin receptor agonists become a treatment option for pediatric chronic immune thrombocytopenia in the future?
Gregory Cheng
Clinical Trail Perspective: Clinical Investigation
-
Will thrombopoietin receptor agonists become a treatment option for pediatric chronic immune thrombocytopenia in the future?
Gregory Cheng
Clinical Trail Perspective: Clinical Investigation
-
Will thrombopoietin receptor agonists become a treatment option for pediatric chronic immune thrombocytopenia in the future?
Gregory Cheng
Clinical Trail Perspective: Clinical Investigation
-
Sustained and rapid virological responses in hepatitis C clinical trials
Akihito Tsubota, Tomomi Furihata, Yoshihiro Matsumoto, Kan Chiba
Clinical Trail Prospective: Clinical Investigation
-
Sustained and rapid virological responses in hepatitis C clinical trials
Akihito Tsubota, Tomomi Furihata, Yoshihiro Matsumoto, Kan Chiba
Clinical Trail Prospective: Clinical Investigation
-
Sustained and rapid virological responses in hepatitis C clinical trials
Akihito Tsubota, Tomomi Furihata, Yoshihiro Matsumoto, Kan Chiba
Clinical Trail Prospective: Clinical Investigation
-
Sustained and rapid virological responses in hepatitis C clinical trials
Akihito Tsubota, Tomomi Furihata, Yoshihiro Matsumoto, Kan Chiba
Clinical Trail Prospective: Clinical Investigation
-
Sustained and rapid virological responses in hepatitis C clinical trials
Akihito Tsubota, Tomomi Furihata, Yoshihiro Matsumoto, Kan Chiba
Clinical Trail Prospective: Clinical Investigation
-
Sustained and rapid virological responses in hepatitis C clinical trials
Akihito Tsubota, Tomomi Furihata, Yoshihiro Matsumoto, Kan Chiba
Clinical Trail Prospective: Clinical Investigation
-
Emerging therapies for the treatment of uveitis: clinical trial observations
Jamie Lynne Metzinger, C Stephen Foster
Review: Clinical Trail Outcomes: Clinical Investigation
-
Emerging therapies for the treatment of uveitis: clinical trial observations
Jamie Lynne Metzinger, C Stephen Foster
Review: Clinical Trail Outcomes: Clinical Investigation
-
Emerging therapies for the treatment of uveitis: clinical trial observations
Jamie Lynne Metzinger, C Stephen Foster
Review: Clinical Trail Outcomes: Clinical Investigation
-
Emerging therapies for the treatment of uveitis: clinical trial observations
Jamie Lynne Metzinger, C Stephen Foster
Review: Clinical Trail Outcomes: Clinical Investigation
-
Emerging therapies for the treatment of uveitis: clinical trial observations
Jamie Lynne Metzinger, C Stephen Foster
Review: Clinical Trail Outcomes: Clinical Investigation
-
Emerging therapies for the treatment of uveitis: clinical trial observations
Jamie Lynne Metzinger, C Stephen Foster
Review: Clinical Trail Outcomes: Clinical Investigation
-
Genetic biomarkers of placebo response: what could it mean for future trial design?
Kathryn T Hall & Ted J Kaptchuk
Editorial: Clinical Investigation
-
Genetic biomarkers of placebo response: what could it mean for future trial design?
Kathryn T Hall & Ted J Kaptchuk
Editorial: Clinical Investigation
-
Genetic biomarkers of placebo response: what could it mean for future trial design?
Kathryn T Hall & Ted J Kaptchuk
Editorial: Clinical Investigation
-
Genetic biomarkers of placebo response: what could it mean for future trial design?
Kathryn T Hall & Ted J Kaptchuk
Editorial: Clinical Investigation
-
Genetic biomarkers of placebo response: what could it mean for future trial design?
Kathryn T Hall & Ted J Kaptchuk
Editorial: Clinical Investigation
-
Genetic biomarkers of placebo response: what could it mean for future trial design?
Kathryn T Hall & Ted J Kaptchuk
Editorial: Clinical Investigation
-
Everolimus for the treatment of advanced pancreatic neuroendocrine tumors
Paola Tomassetti, Monica Cevenini, Elena Guidetti, Giulia Cacciari, Maria Luigia Cipollini, Elena Galassi, Maria Camilla Fabbri, Francesca Nori, Davide Campana, Roberto Corinaldesi ,Roberto De Giorgio
Review: Clinical Trail Outcomes: Clinical Investigation
-
Everolimus for the treatment of advanced pancreatic neuroendocrine tumors
Paola Tomassetti, Monica Cevenini, Elena Guidetti, Giulia Cacciari, Maria Luigia Cipollini, Elena Galassi, Maria Camilla Fabbri, Francesca Nori, Davide Campana, Roberto Corinaldesi ,Roberto De Giorgio
Review: Clinical Trail Outcomes: Clinical Investigation
-
Everolimus for the treatment of advanced pancreatic neuroendocrine tumors
Paola Tomassetti, Monica Cevenini, Elena Guidetti, Giulia Cacciari, Maria Luigia Cipollini, Elena Galassi, Maria Camilla Fabbri, Francesca Nori, Davide Campana, Roberto Corinaldesi ,Roberto De Giorgio
Review: Clinical Trail Outcomes: Clinical Investigation
-
Everolimus for the treatment of advanced pancreatic neuroendocrine tumors
Paola Tomassetti, Monica Cevenini, Elena Guidetti, Giulia Cacciari, Maria Luigia Cipollini, Elena Galassi, Maria Camilla Fabbri, Francesca Nori, Davide Campana, Roberto Corinaldesi ,Roberto De Giorgio
Review: Clinical Trail Outcomes: Clinical Investigation
-
Everolimus for the treatment of advanced pancreatic neuroendocrine tumors
Paola Tomassetti, Monica Cevenini, Elena Guidetti, Giulia Cacciari, Maria Luigia Cipollini, Elena Galassi, Maria Camilla Fabbri, Francesca Nori, Davide Campana, Roberto Corinaldesi ,Roberto De Giorgio
Review: Clinical Trail Outcomes: Clinical Investigation
-
Everolimus for the treatment of advanced pancreatic neuroendocrine tumors
Paola Tomassetti, Monica Cevenini, Elena Guidetti, Giulia Cacciari, Maria Luigia Cipollini, Elena Galassi, Maria Camilla Fabbri, Francesca Nori, Davide Campana, Roberto Corinaldesi ,Roberto De Giorgio
Review: Clinical Trail Outcomes: Clinical Investigation